DMH1 Increases Glucose Metabolism through Activating Akt in L6 Rat Skeletal Muscle Cells

Xin Xie, Xiao-Ming Xu, Na Li, Yong-Hui Zhang, Yu Zhao, Chun-Yan Ma, De-Li Dong*

Department of Pharmacology (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, P.R. China

Abstract

DMH1(4-[6-(4-Isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl] quinoline) is a compound C analogue with the structural modifications at the 3- and 6-positions in pyrazolo[1,5-a]pyrimidine backbone. Compound C was reported to inhibit both AMPK and Akt. Our preliminary work found that DMH1 activated Akt. Since Akt was involved in glucose metabolism, we aimed to identify the effects of DMH1 on glucose metabolism in L6 rat muscle cells and the potential mechanism. Results showed that DMH1 increased lactic acid release and glucose consumption in L6 rat muscle cells in a dose-dependent manner. DMH1 activated Akt in L6 cells. Akt inhibitor inhibited DMH1-induced Akt activation and DMH1-induced increases of glucose uptake and consumption. DMH1 had no cytotoxicity in L6 cells, but inhibited mitochondrial function and reduced ATP production. DMH1 showed no effect on AMPK, but in the presence of Akt inhibitor, DMH1 significantly activated AMPK. Compound C inhibited DMH1-induced Akt activation in L6 cells. Compound C inhibited DMH1-induced increase of glucose uptake, consumption and lactic acid release in L6 cells. DMH1 inhibited PP2A activity, and PP2A activator forskolin reversed DMH1-induced Akt activation. We concluded that DMH1 increased glucose metabolism through activating Akt and DMH1 activated Akt through inhibiting PP2A activity in L6 rat muscle cells. In view of the analogue structure of DMH1 and compound C and the contrasting effects of DMH1 and compound C on Akt, the present study provides a novel leading chemical structure targeting Akt with potential use for regulating glucose metabolism.

Introduction

Compound C is an AMP-activated protein kinase (AMPK) inhibitor and is widely used in the studies related to AMPK. For example, it was reported that AMPK inhibition by compound C prevented glucose uptake induced by testosterone in cardiomyocytes [1], attenuated LPS-induced immune responses and liver injury [2]. However, several studies have shown that compound C also exerted its action in an AMPK-independent manner. Vucicevic et al. found that compound C induced autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway [3]. DMH1(4-[6-(4-Isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl] quinoline) was a compound C analogue with the structural modifications at the 3- and 6-positions in pyrazolo[1,5-a]pyrimidine backbone [4]. DMH1 was initially developed as a bone morphogenetic protein (BMP) selective inhibitor [4] and our preliminary work showed that DMH1 activated Akt in L6 cells.

Protein kinase B (Akt) and AMPK play important roles in regulating the glycolysis process. Akt is a serine/threonine-specific protein kinase involved in multiple cellular processes such as glucose metabolism and cell proliferation. AMPK regulates metabolic pathways to balance energy at both cellular and whole-body levels [5,6]. Since Akt was involved in glycolysis, we aimed to identify the effects of DMH1 on glucose metabolism in L6 rat muscle cells that are generally used in glycolysis studies. Because both DMH1 and compound C have the similar chemical structure, we further compared the effects of compound C with DMH1, looking forward to providing a novel clue on development of drugs regulating glucose metabolism based on the structure and pharmacological effects of DMH1 and compound C.

Materials and Methods

Agents

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) were purchased from HyClone. DMH1, compound C, Akt1/2 kinase inhibitor (1,3-Dihydro-1-1-1-[4-(6-phenyl-1H-imidazo[1,5-g]quinolin-7-yl)phenyl(methyl)-1-piperidinyl]-2H-benzimidazol-2-one trifluoroacetate salt hydrate) and insulin were obtained from Sigma-Aldrich. Rat L6 skeletal muscle cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. Live/dead Viability/Cytotoxicity Assay kit was obtained from Invitrogen. DMEM glucose free was obtained from Gibco. Anti-phospho-Akt Ser473, anti-Akt, anti-phospho-AMPK Thr172, anti-AMPK and PP2A antibodies were obtained from Cell Signaling Technology. Glucose uptake cell-based assay kit was obtained from Cayman Chemical Company. Glucose assay kit, lactic acid assay kit, and lactate dehydrogenase (LDH) assay kit were

Citation: Xie X, Xu X-M, Li N, Zhang Y-H, Zhao Y, et al. (2014) DMH1 Increases Glucose Metabolism through Activating Akt in L6 Rat Skeletal Muscle Cells. PLoS ONE 9(9): e107776. doi:10.1371/journal.pone.0107776

Editor: Yu Huang, The Chinese University of Hong Kong, Hong Kong

Received January 19, 2014; Accepted August 21, 2014; Published September 23, 2014

Copyright: © 2014 Xie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Natural Science Foundation of China (81373406, 81173049, 81121003), Chang Jiang Scholar Candidates Program for Provincial Universities in Heilongjiang (2011CJHB002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: dongdeli@ems.hrbmu.edu.cn
purchased from Nanjing Jiancheng Bioengineering Institute (China). ATP assay kit and PP2A agonist forskolin were purchased from Beyotime Institute of Biotechnology (China).

Cell culture

L6 skeletal muscle cells were grown in Dulbecco’s modified Eagle’s medium containing 5.5 mmol/l glucose and supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2. The time of treatment and the concentration of agents were shown in figures and/or figure legends.

Measurement of glucose consumption and lactic acid content

The cells were grown in 6-well plates. After the indicated periods of incubation with different treatments, the culture medium was collected; the glucose concentration in the medium was determined by the glucose oxidase method (Nanjing Jiancheng Biological Engineering Research Institute, China). The amount of lactic acid in the medium was measured by a commercial assay according to the instruction (Nanjing Jiancheng Biological Engineering Research Institute, China). In brief, pyruvic acid was produced from lactic acid with reduction of NAD+ to NADH. Simultaneously, the tetranitroblue tetrazolium chloride (NBT) was also reduced to purple colored substances whose absorbance was read at 530 nm using a plate reader.

Glucose uptake assay

Cells (5×10⁴ cells) were seeded in a 96-well black and clear bottom plate with 100 µl culture medium. After incubation at 37°C, 5% CO₂ overnight, the medium was replaced with glucose-free medium containing 150 µg/ml 2-NBDG (a fluorescently-labeled deoxyglucose analog). Then cells were exposed to DMH1 or compound C, or Akt1/2 kinase inhibitor for 24 hrs. The plate was centrifuged for 5 min at 400×g at room temperature, the supernatant was aspirated, and then 200 µl cell-based assay buffer was added and centrifuged again. Next, the supernatant was aspirated and 100 µl cell-based assay buffer was added again. The fluorescein at a wavelength of excitation/emission = 485/535 nm was measured with a plate reader (Tecan Infinite m200, Mannedorf, Switzerland).

Measurement of intracellular ATP and SDH activity

Cells were washed twice with PBS solution and then resolved in lysis buffer on ice. ATP was measured by luminometric methods using commercially available luciferin/luciferase reagents according to the manufacturer’s instructions (ATP Assay Kit; Beyotime Biotech). Finally, ATP concentration was normalized to the protein levels. Succinatedehydrogenase (SDH) activity was measured by MTT assay. Cells were treated with different concentrations of DMH1 for 24 hrs and then incubated with 5 mg/ml MTT for 4 hrs at 37°C. Medium was then removed and 200 µl of DMSO was added to dissolve the crystal. Absorbance was measured at 530 nm using a plate reader.

![Figure 1. Dose- and time-dependent stimulation of lactic acid release in L6 cells by DMH1.](image1)

A) L6 cells were incubated with incremental concentrations of DMH1 for 24 hrs. n = 6. (B) L6 cells were incubated with 10 µM DMH1 at different incubation periods up to 24 hrs. n = 6. *P<0.05, **P<0.01 vs control.

doi:10.1371/journal.pone.0107776.g001

![Figure 2. DMH1 increases glucose consumption in a dose- and time-dependent manner in L6 cells.](image2)

A) L6 cells were incubated with 0.1 µM, 1 µM, 5 µM and 10 µM DMH1 for 24 hrs. n = 10. (B) L6 cells were incubated with 10 µM DMH1 for 1, 3, 6, 12 and 24 hrs. Glucose consumption was normalized to total protein level. n = 11.*P<0.05, **P<0.01 vs control.

doi:10.1371/journal.pone.0107776.g002
measured at a wavelength of 490 nm with a plate reader (Tecan Infinite m200, Mannedorf, Switzerland).

Lactate dehydrogenase (LDH) activity assay

Cells were treated with different concentration of DMH1 for 24 hrs, then cell culture medium was collected for LDH determination. LDH could catalyze the synthesis of pyruvic acid from lactic acid and then pyruvic acid reacted to form 2,4-dinitrophenyl-hydrazine which showed brownish red color in basic solution. After the reaction, the absorbance was read at wavelength 450 nm.

Live and dead cell staining

The LIVE/DEAD Viability/Cytotoxicity Assay Kit (Invitrogen) was used to detect live and dead cells as described in our previous work [7]. Briefly, cells were grown on coverslips at a density of 3.75 × 10^4/ml and incubated overnight at 37°C in a humidified 5% CO2 incubator. The cells were washed with PBS and dyed according to the manufacturer’s instructions. The labeled cells were photographed under a fluorescence microscope. The live cells fluoresce green and dead cells fluoresce red.

Western blot analysis

Detailed information was described in our previous works [7,8]. Western blot bands were quantified by using Odyssey infrared imaging system (LI-COR) and Odyssey v3.0 software.

PP2A activity assay

PP2A activity was determined by using the PP2A Immunoprecipitation Phosphatase Assay Kit (Millipore, US), assessed by dephosphorylation of the phosphopeptide (K-R-pT-I-R-R).

Data analysis

Data are presented as mean±SEM. Significance was determined by using Student t test. P<0.05 was considered significant.

Results

DMH1 increases lactic acid release

Firstly, we measured the effects of DMH1 on lactic acid release in L6 rat muscle cells. As shown in Figure 1A, the lactic acid concentration was increased in the culture medium in a dose-dependent manner by DMH1 treatment for 24 hrs.
results indicated that 10 μM DMH1 increased lactic acid release at 12 hrs after DMH1 treatment (Figure 1B). Lactic acid is the product of anaerobic glycolysis. These results indicated that DMH1 stimulated anaerobic glycolysis.

DMH1 increases glucose consumption

Next, we measured the effects of DMH1 on glucose consumption in L6 rat muscle cells. As shown in Figure 2A, DMH1 treatment increased glucose consumption in a dose-dependent manner. Time course results indicated that 10 μM DMH1 increased glucose consumption at 12 hrs after DMH1 treatment (Figure 2B). Based on the above data, we used DMH1 at 10 μM concentration and the time of DMH1 treatment was set as 24 hrs.

DMH1 activates Akt in L6 cells

Compound C, a DMH1 analogue, inhibited Akt [3]. Here, we examined the effects of DMH1 on Akt in L6 cells. As shown in Figure 3A, DMH1 stimulated the phosphorylation of Akt which was also inhibited by Akt inhibitor (Figure 3B). Since Akt activation was involved in glucose uptake and consumption [9,10], we measured the effects of Akt inhibitor on the increased glucose uptake, consumption and lactic acid release induced by DMH1 treatment. As shown in Figure 3C–3E, DMH1-induced increase of glucose uptake, consumption and lactic acid release was inhibited by Akt inhibitor, indicating that DMH1 increased glucose uptake, consumption and lactic acid release through activating Akt in L6 cells. Akt inhibitor (0.5 μM) alone showed no significant effects on

Figure 4. DMH1 has no cytotoxicity, but inhibited SDH activity and ATP production. (A) DMH1 did not increase LDH release in L6 cells. Cells were incubated with 1 μM, 5 μM and 10 μM DMH1 for 24 hrs. Then LDH units were normalized to total protein content. n = 5. (B) Representative photographs showing that DMH1 did not induce cell death. Cells were treated with 10 μM DMH1 for 24 hrs. The labeled cells were photographed under a fluorescence microscope. The live cells fluoresce green and dead cells fluoresce red. (C) MTT results showed that DMH1 inhibited succinate dehydrogenase (SDH) activity. n = 24. **P<0.01 vs control. (D) DMH1 treatment reduced ATP production in L6 cells. n = 6. **P<0.01 vs control.

doi:10.1371/journal.pone.0107776.g004

Figure 5. Effects of DMH1 on the phosphorylation of AMPK. (A) Representative western blot results showed that DMH1 did not affect phosphorylation of AMPK in L6 cells. The western blot represented three individual experiments. (B) DMH1(10 μM) activated AMPK in the presence of Akt inhibitor (0.5 μM). **P<0.01 vs Akti. Akti, Akt inhibitor, (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one trifluoroacetate salt hydrate).

doi:10.1371/journal.pone.0107776.g005
glucose consumption and lactic acid release, though Akt inhibitor inhibited p-Akt level in L6 cells (Figure.3F–3H). We further used Akt siRNA which had been proved to knockdown Akt expression in our previous work [11], to test the effect of DMH1 on glucose consumption. Results showed that Akt siRNA inhibited DMH1-induced increase of glucose consumption in L6 cells (Figure.3I).

DMH1 has no cytotoxicity in L6 cells

In this study, the cells were treated with DMH1 for 24 hrs, so it was necessary to examine whether DMH1 had cytotoxicity in L6 cells. LDH cytotoxicity assay and LIVE/DEAD viability assay were used to address this issue. As shown in Figure.4A, DMH1 treatment did not increase LDH release during exposure to 1, 5, 10 μM DMH1 for 24 hrs. LIVE/DEAD viability assay results also showed that DMH1 had no cytotoxicity in L6 cells (Figure.4B). MTT assay was commonly used to evaluate mitochondrial succinate dehydrogenase activity, based on the fact that viable cells can reduce 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). Succinate dehydrogenase is a marker enzyme reflecting the mitochondrial function for producing ATP [12,13]. Since DMH1 had no cytotoxicity in L6 cells, MTT results indicated that DMH1 inhibited mitochondrial function (Figure.4C). Indeed, DMH1 reduced ATP levels in L6 cells in a dose-dependent manner (Figure.4D).

Activation of AMPK is often a consequence of a decrease of ATP production or an increase of AMP/ATP ratio [5,14]. Since DMH1 reduced ATP levels in L6 cells, it would be expected that DMH1 could activate AMPK. However, we did not detect the significant activation of AMPK in L6 cells treated with DMH1 (Figure.5A). Next, we treated L6 cells with DMH1 in the presence of Akt inhibitor. Results showed that DMH1 significantly activated AMPK in the presence of Akt inhibitor (Figure.5B), indicating that DMH1 activated AMPK when Akt was inhibited by Akt inhibitor. Akt is a negative regulator of AMPK [15,16], we speculated that AMPK activated by DMH1-induced decrease of ATP could be inhibited by DMH1-induced activation of Akt, so the activation of AMPK was not observed.

Compound C inhibits DMH1-induced Akt activation in L6 cells

Compound C was reported to block Akt pathway in cancer cells [3]. Here, we found compound C inhibited DMH1-induced Akt activation in L6 cells (Figure.6A). Next, we treated L6 cells with DMH1 and DMH1 plus compound C in the presence of Akt inhibitor. Results showed that DMH1 still activated Akt in L6 cells which were pretreated with Akt inhibitor, but when the cells were co-treated with compound C, the activated Akt was almost completely inhibited (Figure.6B).

Then we measured the effects of compound C on DMH1-induced increase of glucose uptake, consumption and lactic acid release. As shown in Figure.6C–6E, compound C inhibited DMH1-induced increase of glucose uptake, consumption and lactic acid release, though Akt inhibitor inhibited p-Akt level in L6 cells (Figure.3F–3H). We further used Akt siRNA which had been proved to knockdown Akt expression in our previous work [11], to test the effect of DMH1 on glucose consumption. Results showed that Akt siRNA inhibited DMH1-induced increase of glucose consumption in L6 cells (Figure.3I).

DMH1 Increases Glucose Metabolism

Figure 6. Compound C inhibited DMH1-induced activation of Akt, increases of glucose uptake, glucose consumption, and lactic acid release. (A) Western blot results showed that compound C inhibited DMH1-induced Akt activation in L6 cells. **P<0.01 vs control; ### P<0.01 vs DMH1. (B) Compound C completely inhibited Akt activated by DMH1 in the presence of Akt inhibitor. *P<0.05 vs Akti; ## P<0.05 vs Akti+DMH1. (C–E) Compound C inhibited DMH1-induced increases of glucose uptake, glucose consumption, and lactic acid release. **P<0.01 vs control. # P<0.05, ### P<0.01 vs DMH1. (F–H) Compound C alone inhibited glucose consumption, lactic acid release and p-Akt level in L6 cells. *P<0.05, **P<0.01 vs control. The concentrations of DMH1, compound C and Akti were 10 μM, 10 μM, and 0.5 μM respectively. Akti, Akt inhibitor, (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one trifluoroacetate salt hydrate). doi:10.1371/journal.pone.0107776.g006
lactic acid release. Compound C alone also inhibited glucose consumption, lactic acid release and p-Akt level in L6 cells (Figure.6F–6H).

DMH1 was first developed as a potent and selective inhibitor of BMP signaling [4]. Recent studies reported that DMH1 had
multiple effects, for example, DMH1 increased cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells [22], promoted neurogenesis of hiPSCs [23]. Our earlier studies found that DMH1 inhibited pathological cardiac hypertrophy and its related Kv4.3 K⁺ channel remodeling [8,19]. Here, we showed that DMH1 increased glucose metabolism through activating Akt and DMH1 activated Akt through inhibiting PI3K/Akt and cell death in bovine aortic endothelial cells, suggesting that PI3K/Akt plays critical regulatory roles in hyperglycemia induced cell demise [26]. In primary rat hepatocytes, palmitate incubation resulted in a significant inhibition of insulin-mediated Akt activation and a significant increase in PI3K/Akt expression and activity. Pharmacological inhibition of PI3K restored insulin-induced Akt activation in palmitate-treated cells [27]. Based on the pathological role of PI3K/Akt hyperactivation in diabetes, we thought that the present work put forward a novel PI3K/Akt inhibitor with potential use for mitigating diabetic derangement.

Both Akt and AMPK activation lead to increase of glucose metabolism, but it is unnecessary to activate both Akt and AMPK at the same time. For example, ciliary neurotrophic factor increases muscle glucose uptake by a mechanism involving the Akt pathway that does not require AMPK [8,20]. We found that DMH1 increased glucose metabolism through activating Akt in L6 rat skeletal muscle cells, and Akt inhibitor and compound C inhibited DMH1-induced increase of glucose metabolism. Although compound C is commonly used as AMPK inhibitor, here, we thought that compound C inhibited DMH1-induced increase of glucose metabolism through inhibiting Akt.

**Author Contributions**

Conceived and designed the experiments: DLD. Performed the experiments: XX XMX NI YHZ YZ CYM. Analyzed the data: XX DLD. Wrote the paper: DLD.

**References**

1. Wilson C, Contreras-Ferrat A, Vrnegas N, Osorio-Fuentes C, Pavez M, et al. (2013) Testosterone increases GLUT4-dependent glucose uptake in cardiomyocytes. J Cell Physiol 228: 2399-2407. doi:10.1002/jcp.24413.
2. Guo Y, Zhang Y, Hong K, Luo F, Gu Q, et al. (2014) AMPK inhibition blocks ROS-NKappaB signaling and attenuates endothelium-induced liver injury. PloS One 9 e89801. doi:10.1371/journal.pone.0089801. eCollection 2014.
3. Vucicevic L, Misiric J, Janjetovic K, Vilimanovich U, Suard E, et al. (2011) Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 7: 40-50. doi:10.4161/auto.7.1.11083.
4. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, et al. (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 5: 243-253. doi:10.1021/cb900296s.
5. Gabe BB, Alquini T, Garling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25. doi:10.1016/j.cmet.2004.12.003.
6. Hardie DG (2008) AMPK, a key regulator of energy balance in the single cell and the whole organism. Int J Obesity (Lond) 32 Suppl 4: S7-12. doi:10.1038/ sj.ijo.2008.116.
7. Li Q, Zhang Y, Sheng Y, Hua R, Sun B, et al. (2012) Large-T antigen up-regulates Kv4.3 K⁺ channels through Sp1, and Kv4.3 K⁺ channels contribute to cell apoptosis and necrosis through activation of calcium/calcium-dependent protein kinase II. Biochem J 441: 859-867. doi:10.1042/Bj20111604.
8. Sun B, Hua R, Sheng Y, Li X, Xie X, et al. (2013) Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension 61: 352-360. doi:10.1161/HYPERTENSIONAHA.111.00562.
9. Choi SS, Chia BY, Choi BK, Lee VS, Yonezawa T, et al. (2013) Fargesin, a component of Flos Magnoliæ, stimulates glucose uptake in L6 myotubes. J Nat Med 67: 329-328. doi:10.1007/s11011-012-0255-3.
10. Ruanhain JC, Fox CJ, Plo DR, Hammerman PS, Ginali RM, et al. (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth-factor-independent survival. Mol Cell Biol 23: 7315–7328. doi:10.1128/MCB.23.20.7315-7328.2003.
11. Sheng Y, Sun B, Guo WT, Liu X, Wang YG, et al. (2014) DMH1: 4-(6-iso- propoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl quinoline is a novel autophagy inhibitor. Br J Pharmacol. doi:10.1111/bph.12821.
12. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgovin M, et al. (1995) Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 11: 144-149. doi:10.1038/ng1954-144.
13. Pollard PJ, Wortham GC, Tomlinson IP (2003) The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 35: 632-639. doi:10.1080/0785393050018458.
14. Hardie DG, Scott JW, Pan DA, Hudson ER (2003) Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546: 113-120. doi:10.1016/S0014-5793(03)05650-X.
15. Kovacic S, Sohys CL, Barr AJ, Shogima I, Walsh K, et al. (2003) Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278: 39422-39427. doi:10.1074/jbc.M303571200.
16. Hahn-Windgassen A, Nogueira V, Chen CC, Sleen JE, Sonenberg N, et al. (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089. doi:10.1074/jbc.M502076200.
17. Millward TA, Zohlerwics Z, Hemmings BA (1999) Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191. doi:10.1016/S0968-0005(99)01375-4.
18. Jansonov V, Garci J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439.
19. Ugi S, Inamura T, Maegawa H, Egawa K, Yoshizaki T, et al. (2004) Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24: 8778–8789. doi:10.1128/MCB.24.19.8778-8789.2004.
20. Feschenko MS, Stevenson E, Nairn AC, Sweadner KJ (2002) A novel CAMP-stimulated protein phosphatase 2A activation. J Pharmacol Exp Ther 302: 111-118. doi:10.1124/jpet.302.1.111.
21. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, et al. (2005) The tumor suppressor PI3Kα is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer cell 8: 355-366. doi:10.1016/j.ccr.2005.10.015.
22. Ao A, Hua J, Hopkins CR, Hong CC (2012) DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS one 7: e41627. doi:10.1371/journal.pone.0041627.
23. Neely MD, Litt MJ, Tidball AM, Li GG, Aboud AA, et al. (2012) DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci 3: 482–491. doi:10.1021/cn3000929.
24. Sun B, Sheng Y, Hua R, Hu CW, Lu J, et al. (2013) Bone morphogenetic protein-4 contributes to the down-regulation of Kv4.3 K⁺ channels in pathological cardiac hypertrophy. Biochem Biophys Res Commun 436: 591-596. doi:10.1016/j.bbrc.2013.03.113.
25. Kowshur A, Matti A (2012) Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: potential mechanisms and functional consequences. Biochem Pharmacol 84: 591–597. doi:10.1016/j.bcp.2012.05.003.
26. Du Y, Kowshur A, Kern TS (2010) PI3K/Akt contributes to endothelial death in high glucose: inhibition by benfotiamine. Am J Physiol Regul Integr Comp Physiol 299: R1610–1617. doi:10.1152/ajpregu.00676.2009.
27. Galbo T, Olsen GS, Quistorff B, Nishimura E (2011) Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. PLoS one 6: e27424. doi: 10.1371/journal.pone.0027424.

28. Steinberg GR, Watt MJ, Ernst M, Birnbaum MJ, Kemp BE, et al. (2009) Ciliary neurotrophic factor stimulates muscle glucose uptake by a PI3-kinase-dependent pathway that is impaired with obesity. Diabetes 58: 829–839. doi: 10.2337/db08-0659.